- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeffrey Lowenkron Discusses the Impacts of Medicare Advantage Expansion on Oncology Care
The expansion of Medicare Advantage benefits patients, but presents challenges in oncology care, said Jeffrey Lowenkron, MD, chief medical officer of The Villages Health.
The expansion of Medicare Advantage benefits patients, but presents challenges in oncology care, said Jeffrey Lowenkron, MD, chief medical officer of The Villages Health.
Transcript:
Is the expansion of Medicare Advantage a plus or a minus for oncology care, in your view?
I think the expansion of Medicare Advantage, it's always a plus for the patient. Because what Medicare Advantage does, as opposed to the fee-for-service world, is it links and aligns patient outcomes with care delivery. As patients do better, the care delivery systems do better, and as patients do worse, the care delivery systems do worse. In the typical fee-for-service model, generally the care delivery system can do really, really well, and the patients may do very, very poorly. They don't have to align. So from the perspective of the patients, it's always a better care model and payment model to be in Medicare Advantage than traditional fee-for-service.
From the oncology perspective specifically, there are going to be some challenges because obviously with the expansiveness of very expensive medications in the oncology world, the difficulty of figuring out how to pay for those, is a real challenge. I can't tell you whether it's going to be better or worse for them over time.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
